TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32462206

Group type: EXPERIMENTAL
Intervention: Topical Body Firming Moisturizer (TBFM) applied twice daily for 12 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo moisturizer applied twice daily for 12 weeks
Number of subjects: 40
Study: 32991650

Group type: COMPARATOR
Intervention: SAC Assessment Tool used by control dentist
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SAC Assessment Tool used by dentists 1, 2, and 3
Number of subjects: 30

Group type: COMPARATOR
Intervention: No SAC Assessment Tool used by control dentist
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: No SAC Assessment Tool used by dentists 1, 2, and 3
Number of subjects: 30
Study: 33278832

Group type: EXPERIMENTAL
Intervention: Warfarin (GFR ≥ 45–59)
Number of subjects: 56034

Group type: EXPERIMENTAL
Intervention: Warfarin (GFR < 45)
Number of subjects: 56034

Group type: EXPERIMENTAL
Intervention: Warfarin (ARISTOTLE and ENGAGE trials, GFR ≥ 45–59)
Number of subjects: 56034

Group type: EXPERIMENTAL
Intervention: Warfarin (ARISTOTLE and ENGAGE trials, GFR < 45)
Number of subjects: 56034

Group type: EXPERIMENTAL
Intervention: Dabigatran (GFR ≥ 45–59)
Number of subjects: 56034

Group type: EXPERIMENTAL
Intervention: Dabigatran (GFR < 45)
Number of subjects: 56034

Group type: EXPERIMENTAL
Intervention: Dabigatran (GFR < 60)
Number of subjects: 56034

Group type: EXPERIMENTAL
Intervention: Edoxaban (GFR ≥ 45–59)
Number of subjects: 56034

Group type: EXPERIMENTAL
Intervention: Edoxaban (GFR < 45)
Number of subjects: 56034

Group type: EXPERIMENTAL
Intervention: Edoxaban (GFR < 60)
Number of subjects: 56034

Group type: EXPERIMENTAL
Intervention: Apixaban (GFR ≥ 45–59)
Number of subjects: 56034

Group type: EXPERIMENTAL
Intervention: Apixaban (GFR < 45)
Number of subjects: 56034

Group type: EXPERIMENTAL
Intervention: Apixaban and Edoxaban (GFR ≥ 45–59)
Number of subjects: 56034

Group type: EXPERIMENTAL
Intervention: Apixaban and Edoxaban (GFR < 45)
Number of subjects: 56034
Study: 32513646

Group type: EXPERIMENTAL
Intervention: HappyAir group (mHealth web-based platform)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (scheduled check-ups)
Number of subjects: 44
Study: 34854112

Group type: EXPERIMENTAL
Intervention: 0.75% metronidazole gel
Number of subjects: 130

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 130
Study: 33600014

Group type: EXPERIMENTAL
Intervention: HIIT (n = 26)
Number of subjects: 40

Group type: COMPARATOR
Intervention: CON (n = 14)
Number of subjects: 40
Study: 33085861

Group type: EXPERIMENTAL
Intervention: AK002 (combined low-dose and high-dose)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 35077261

Group type: EXPERIMENTAL
Intervention: Rapid initiation of CPB (15 seconds)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Slow initiation of CPB (180 seconds)
Number of subjects: 0
Study: 32873104

Group type: EXPERIMENTAL
Intervention: Mechanical Thrombectomy (MT)
Number of subjects: 100
Study: 32599071

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 559

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 559
Study: 34004416

Group type: EXPERIMENTAL
Intervention: ResistAid (15 g/d)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Maltodextrin (control, 15 g/d)
Number of subjects: 30
Study: 36336861

Group type: EXPERIMENTAL
Intervention: Single high oral dose of vitamin D3 (120,000 IU)
Number of subjects: 58
Study: 34082737

Group type: EXPERIMENTAL
Intervention: Effective communication skills training (7 sessions of 45 min each)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 94
Study: 32859032

Group type: EXPERIMENTAL
Intervention: Low glutamate diet
Number of subjects: 40

Group type: COMPARATOR
Intervention: Monosodium glutamate (MSG)/placebo
Number of subjects: 40
Study: 33616612

Group type: EXPERIMENTAL
Intervention: Nilotinib
Number of subjects: 0
Study: 32404181

Group type: EXPERIMENTAL
Intervention: Height-adjustable workstation
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Education seminar
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Feedback on sitting time
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Darma cushion
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Action planning/goal setting diary
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Overall benefits
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group feedback
Number of subjects: 58
Study: 35991134

Group type: EXPERIMENTAL
Intervention: Individualized nursing
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine nursing
Number of subjects: 40
Study: 33805193

Group type: EXPERIMENTAL
Intervention: Kinesio tape (KT) applied to 20 patients (21 elbows)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Corticosteroid injection (CSI) applied to 15 patients (17 elbows)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Rest-and-medication group (RMG) with 15 patients
Number of subjects: 50
Study: 32619050

Group type: EXPERIMENTAL
Intervention: Super-mini PCNL (SMP)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard percutaneous nephrolithotomy (sPCNL)
Number of subjects: 150
Study: 34941287

Group type: EXPERIMENTAL
Intervention: Live Healthy, Work Healthy (LHWH) program
Number of subjects: 0
Study: 32978204

Group type: EXPERIMENTAL
Intervention: 8-week physiotherapist-supervised strengthening programme for extrinsic and intrinsic foot muscles, three times a week
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group receiving no specific foot intervention and following treatment recommended by the medical team
Number of subjects: 88
Study: 34669318

Group type: EXPERIMENTAL
Intervention: Prophylactic Magnesium supplementation (oral for 5 days before surgery)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (received Magnesium only after evidence of postoperative hypomagnesemia)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups (postoperative Calcium and Magnesium administered to all patients with hypocalcemia and hypomagnesemia)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Correlation analysis between Magnesium, Calcium, and parathyroid hormone
Number of subjects: 120
Study: 36327536

Group type: EXPERIMENTAL
Intervention: Medially‐posted foot orthosis
Number of subjects: 53

Group type: COMPARATOR
Intervention: Flat insert (sham orthosis)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Everyday‐shoe insole (baseline)
Number of subjects: 53
Study: 33003044

Group type: EXPERIMENTAL
Intervention: Electrolyte hydration intervention during 2 of the 3 weeks
Number of subjects: 50
Study: 36328094

Group type: EXPERIMENTAL
Intervention: CHARM2 intervention
Number of subjects: 1201

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1201
Study: 33988725

Group type: EXPERIMENTAL
Intervention: Tradipitant 85 mg/bid
Number of subjects: 8

Group type: COMPARATOR
Intervention: Oxycodone (0 to 30 mg)
Number of subjects: 8
Study: 32565318

Group type: EXPERIMENTAL
Intervention: Neoadjuvant and concurrent ADT for 6 months starting 4 months before prostate radiation therapy (NHT arm)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concurrent and adjuvant ADT for 6 months starting simultaneously with radiation therapy (CAHT arm)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both arms (NHT and CAHT)
Number of subjects: 0
Study: 34215673

Group type: EXPERIMENTAL
Intervention: 68Ga-satoreotide trizoxetan at a peptide mass of 5-20 µg and 30-45 µg with radioactivity ranges of 40-80, 100-140, or 160-200 MBq
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 68Ga-satoreotide trizoxetan PET/CT
Number of subjects: 24

Group type: COMPARATOR
Intervention: Radioactivity range of 40-80 MBq
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 68Ga-satoreotide trizoxetan
Number of subjects: 24
Study: 34419676

Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid photodynamic therapy (5-ALA-PDT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Wide local excision (WLE)
Number of subjects: 36
Study: 35929816

Group type: EXPERIMENTAL
Intervention: Postoperative wound packing
Number of subjects: 433

Group type: COMPARATOR
Intervention: Non-packing
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Packing
Number of subjects: 433
Study: 33185380

Group type: EXPERIMENTAL
Intervention: Aspirin-treated group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Aspirin-naive group
Number of subjects: 80
Study: 35802849

Group type: EXPERIMENTAL
Intervention: Proton craniospinal irradiation (pCSI)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Photon involved-field radiotherapy (IFRT)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Exploratory pCSI group
Number of subjects: 63
Study: 33411779

Group type: EXPERIMENTAL
Intervention: Calm app (mindfulness meditation mobile app), used for ≥10 minutes/day for eight weeks
Number of subjects: 263

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 263
Study: 35607454

Group type: COMPARATOR
Intervention: Normobaric hypoxia (NH)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Shorter inter-set rest periods (60 s)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Hypobaric hypoxia (HH)
Number of subjects: 16
Study: 32799920

Group type: EXPERIMENTAL
Intervention: 6-month community-based lifestyle intervention including group nutrition and health education classes (1 day/week) and group exercise classes (2 days/week)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Usual care control arm
Number of subjects: 117

Group type: COMPARATOR
Intervention: Community recruitment
Number of subjects: 117

Group type: COMPARATOR
Intervention: Clinical recruitment
Number of subjects: 117

Group type: COMPARATOR
Intervention: Media recruitment
Number of subjects: 117
Study: 35130937

Group type: EXPERIMENTAL
Intervention: New Orleans Intervention Model (NIM)
Number of subjects: 390

Group type: COMPARATOR
Intervention: Optimised services as usual (SAU)
Number of subjects: 390
Study: 32122727

Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy (LLLT)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 62
Study: 34851451

Group type: EXPERIMENTAL
Intervention: Endoscopic transcanal tympanoplasty with attico‐antrostomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Endoscopic-assisted canal wall up mastoidectomy
Number of subjects: 40
Study: 33610513

Group type: EXPERIMENTAL
Intervention: Heat-treated colostrum (60 °C, 60 min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Raw colostrum
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Colostrum feeding (both groups)
Number of subjects: 10
Study: 33142541

Group type: EXPERIMENTAL
Intervention: Organic zinc (zinc amino acid complex) at low (35 mg/kg) and high (70 mg/kg) levels
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Inorganic zinc (zinc sulfate) at low (35 mg/kg) and high (70 mg/kg) levels
Number of subjects: 720

Group type: COMPARATOR
Intervention: Control group without supplementary zinc
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Supplemental zinc (both organic and inorganic)
Number of subjects: 720
Study: 36423745

Group type: EXPERIMENTAL
Intervention: ctDNA surveillance with pembrolizumab
Number of subjects: 161

Group type: COMPARATOR
Intervention: Observation (control)
Number of subjects: 161
Study: 32602162

Group type: EXPERIMENTAL
Intervention: 6 weeks of daily Internet gaming
Number of subjects: 104

Group type: COMPARATOR
Intervention: Regular gamers
Number of subjects: 104
Study: 33198538

Group type: EXPERIMENTAL
Intervention: Simulated student performances at four scripted standards: clear fail (CF), borderline (BD), clear pass (CPX), good (GD)
Number of subjects: 120
Study: 32142507

Group type: EXPERIMENTAL
Intervention: Step It Up intervention (5-minute face-to-face discussion, written materials, pedometer, and step chart)
Number of subjects: 1007

Group type: EXPERIMENTAL
Intervention: Step It Up intervention
Number of subjects: 1007
Study: 34949506

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1000 mg, 20 mL) administered intravenously 10 min before surgery
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control (normal saline, 20 mL) administered intravenously
Number of subjects: 66
Study: 32516229

Group type: EXPERIMENTAL
Intervention: Biodesign Surgisis anal fistula plug
Number of subjects: 304

Group type: COMPARATOR
Intervention: Surgeon's preference (advancement flap, cutting seton, fistulotomy, Ligation of the Intersphincteric Fistula Tract procedure)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Surgeon's preference
Number of subjects: 304
Study: 34462287

Group type: EXPERIMENTAL
Intervention: Nivolumab and ipilimumab
Number of subjects: 605

Group type: COMPARATOR
Intervention: Chemotherapy (cisplatin or carboplatin plus pemetrexed)
Number of subjects: 605
Study: 33430948

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 7044

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7044
Study: 34942224

Group type: EXPERIMENTAL
Intervention: cCBT + TAU
Number of subjects: 80

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 80
Study: 33639233

Group type: EXPERIMENTAL
Intervention: POPSAVEIT scoring system
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Risk factors identified in multivariable analysis
Number of subjects: 355
Study: 35007887

Group type: EXPERIMENTAL
Intervention: 6MWT10
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 6MWTF8
Number of subjects: 27

Group type: COMPARATOR
Intervention: 6MWT30
Number of subjects: 27
Study: 32872001

Group type: EXPERIMENTAL
Intervention: CRS followed by HIPEC (CRS+HIPEC; n=14)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided HIPEC followed by delayed CRS (HIPEC+dCRS; n=14)
Number of subjects: 28
Study: 32898921

Group type: EXPERIMENTAL
Intervention: Intervention group receiving predefined feedback between the two intubations
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group receiving no feedback
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 35
Study: 33772118

Group type: EXPERIMENTAL
Intervention: Periodontal treatment
Number of subjects: 48

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 48
Study: 32444573

Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (RAGT) for 5 weeks (3 sessions per week)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Usual care (UC) for 5 weeks
Number of subjects: 16
Study: 34325236

Group type: EXPERIMENTAL
Intervention: Imagery enhanced cognitive restructuring (I-CR)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Traditional cognitive restructuring (CR)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Active control (AC)
Number of subjects: 87
Study: 36195164

Group type: EXPERIMENTAL
Intervention: Intraurethral prilocaine solution
Number of subjects: 128

Group type: COMPARATOR
Intervention: Intraurethral lidocaine gel
Number of subjects: 128
Study: 34468248

Group type: EXPERIMENTAL
Intervention: Pharmacological treatments for COPD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical analysis principles
Number of subjects: 0
Study: 32730613

Group type: EXPERIMENTAL
Intervention: ENABLE CHF‐PC intervention (in‐person palliative care consultation and 6 weekly nurse‐coach telephonic sessions for 16 weeks)
Number of subjects: 415

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: ENABLE CHF‐PC intervention
Number of subjects: 415
Study: 33421590

Group type: EXPERIMENTAL
Intervention: Graded Motor Imagery (GMI) training for 6 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Waiting period (control) for 6 weeks
Number of subjects: 20
Study: 32305531

Group type: EXPERIMENTAL
Intervention: ALPPS procedure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Two stage hepatectomy (TSH)
Number of subjects: 0
Study: 32812324

Group type: EXPERIMENTAL
Intervention: RDN from the adventitia of the renal artery plus adrenalectomy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Adrenalectomy alone (control group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: RDN group
Number of subjects: 60
Study: 35286195

Group type: EXPERIMENTAL
Intervention: Moderate light exposure (100 lx) during sleep
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dimly lit environment (<3 lx) during sleep
Number of subjects: 0
Study: 34852645

Group type: EXPERIMENTAL
Intervention: Bi‐TENS+TOT
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Uni‐TENS+TOT
Number of subjects: 120
Study: 32986238

Group type: EXPERIMENTAL
Intervention: 2016 European Society of Cardiology criteria for HFpEF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2016 echocardiographic algorithm for diagnosing diastolic dysfunction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2018 evidence‐based H2FPEF score
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2019 Heart Failure Association HFA‐PEFF algorithm
Number of subjects: 0
Study: 35711006

Group type: EXPERIMENTAL
Intervention: Odanacatib (ODN)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 36041791

Group type: EXPERIMENTAL
Intervention: Immunosuppressive therapy after 6 months
Number of subjects: 127

Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 127

Group type: COMPARATOR
Intervention: IgAN patients (treatment naive)
Number of subjects: 127
Study: 32088534

Group type: EXPERIMENTAL
Intervention: Epidural block combined with general anesthesia (E + G)
Number of subjects: 70

Group type: COMPARATOR
Intervention: General anesthesia (G)
Number of subjects: 70
Study: 34940841

Group type: EXPERIMENTAL
Intervention: Computer training and use (PRISM system) for 12 months
Number of subjects: 300
Study: 33706573

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy / Mindfulness Based Stress Reduction intervention
Number of subjects: 55

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 55
Study: 32470562

Group type: EXPERIMENTAL
Intervention: Rifaximin 400 mg orally three times daily for 2 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rifaximin
Number of subjects: 0
Study: 36297029

Group type: EXPERIMENTAL
Intervention: Spirulina supplementation (SP group)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo supplementation (PB group)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Delta variations of monocytes
Number of subjects: 39
Study: 34213493

Group type: EXPERIMENTAL
Intervention: Intrathecal nalbuphine (0.5 mL, 0.8 mg) with 3 mL of heavy (0.5%) hyperbaric bupivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intrathecal buprenorphine (0.5 mL, 60 mg) with 3 mL of heavy (0.5%) hyperbaric bupivacaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (nalbuphine and buprenorphine)
Number of subjects: 60
Study: 33591979

Group type: EXPERIMENTAL
Intervention: IDA (ivermectin, diethylcarbamazine and albendazole)
Number of subjects: 8918

Group type: COMPARATOR
Intervention: DA (diethylcarbamazine and albendazole)
Number of subjects: 8918
Study: 36342149

Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen (HBO) combined with X-ray (2 Gy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hyperbaric Oxygen (HBO) (2 Gy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: X-ray (2 Gy)
Number of subjects: 0
Study: 34384597

Group type: COMPARATOR
Intervention: Control group (NSS 20 mL before skin incision and at 3 hours after surgery)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: One-dose (1D) group (750 mg TXA before skin incision and NSS 20 mL at 3 hours after surgery)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Two-dose (2D) group (750 mg TXA before skin incision and 750 mg TXA at 3 hours after surgery)
Number of subjects: 90
Study: 32942770

Group type: EXPERIMENTAL
Intervention: Generalized Anxiety Disorder (GAD)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Post‐Traumatic Stress Disorder (PTSD)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Major Depressive Disorder (MDD)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Factors associated with MDD
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Factors associated with PTSD
Number of subjects: 220
Study: 35121029

Group type: EXPERIMENTAL
Intervention: Nomogram based on LASSO-Cox model
Number of subjects: 495
Study: 34541479

Group type: EXPERIMENTAL
Intervention: ALRV5XR treatment
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 46
Study: 35751704

Group type: EXPERIMENTAL
Intervention: Flowable resin composite (Clearfil Flow FX)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Conventional resin composite (Clearfil AP‐X)
Number of subjects: 19
Study: 32505177

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1.0 μg·kg‐1 for 10 min IV, followed by 0.5 μg·kg‐1·h‐1 throughout procedure)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (saline at identical velocity as Dex group)
Number of subjects: 60
Study: 35679842

Group type: EXPERIMENTAL
Intervention: PNAC
Number of subjects: 174

Group type: COMPARATOR
Intervention: No PNAC
Number of subjects: 174
Study: 34015364

Group type: EXPERIMENTAL
Intervention: Viral contigs identified through sequencing
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Phylogenetic analysis of Mansoniini viruses
Number of subjects: 2
Study: 32216814

Group type: EXPERIMENTAL
Intervention: GSK3008348 (1000 mcg nebulised dose)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 34641800

Group type: EXPERIMENTAL
Intervention: Swaddling group (n=40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Non-swaddling group (n=40)
Number of subjects: 80
Study: 34325518

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (measured by Apnea-Hypopnea Index, AHI)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Obstructive AHI
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Central AHI
Number of subjects: 94
Study: 35256054

Group type: EXPERIMENTAL
Intervention: Intradialytic resistance training (12-week supervised, progressive)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (inactive during dialysis)
Number of subjects: 90
Study: 33492871

Group type: EXPERIMENTAL
Intervention: Anterior iliopsoas muscle space block
Number of subjects: 48

Group type: COMPARATOR
Intervention: Posterior lumbar plexus block
Number of subjects: 48